Find Sotagliflozin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1018899-04-1, Lx-4211, Lx4211, Lp-802034, (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol, 6b4zbs263y
Molecular Formula
C21H25ClO5S
Molecular Weight
424.9  g/mol
InChI Key
QKDRXGFQVGOQKS-CRSSMBPESA-N
FDA UNII
6B4ZBS263Y

Sotagliflozin
Sotagliflozin is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. Upon oral administration, sotagliflozin binds to and blocks both SGLT1 in the gastrointestinal (GI) tract and SGLT2 in the kidneys, thereby suppressing the absorption of glucose from the GI tract and the reabsorption of glucose by the proximal tubule into the bloodstream, respectively. This decreases glucose uptake and enhances the urinary excretion of glucose, which lowers and/or normalizes blood glucose levels. SGLT1 is the primary transporter responsible for glucose absorption from the GI tract. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.
1 2D Structure

Sotagliflozin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol
2.1.2 InChI
InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
2.1.3 InChI Key
QKDRXGFQVGOQKS-CRSSMBPESA-N
2.1.4 Canonical SMILES
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl
2.1.5 Isomeric SMILES
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
2.2 Other Identifiers
2.2.1 UNII
6B4ZBS263Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol

2. Lx-4211

3. Lx4211

2.3.2 Depositor-Supplied Synonyms

1. 1018899-04-1

2. Lx-4211

3. Lx4211

4. Lp-802034

5. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol

6. 6b4zbs263y

7. Sar439954

8. Sar-439954

9. (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol

10. Zynquista

11. Beta-l-xylopyranoside, Methyl 5-c-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5s)-

12. Sotagliflozin [usan:inn]

13. Unii-6b4zbs263y

14. Beta-l-xylopyranoside, Methyl 5-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5s)-

15. Mfcd22493506

16. Lx 4211

17. Lp 802034

18. Sotagliflozin [mi]

19. Sotagliflozin (lx4211)

20. Sotagliflozin [inn]

21. Sotagliflozin (usan/inn)

22. Sotagliflozin [usan]

23. Sotagliflozin (lx-4211)

24. Sotagliflozin [who-dd]

25. Gtpl8312

26. Schembl1038287

27. Chembl3039507

28. Dtxsid20144314

29. Amy12393

30. Ex-a1167

31. Bdbm50235017

32. S8103

33. Zinc95641922

34. Akos025290846

35. Ccg-268940

36. Cs-1069

37. Db12713

38. Ac-29890

39. As-35202

40. Bl161424

41. Hy-15516

42. D10669

43. A852129

44. Q27088840

45. (2s,3r,4r,5s,6r)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-tetrahydro-6-(methylthio)-2h-pyran-3,4,5-triol;lx4211

46. (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2h-pyran-3,4,5-triol

47. .beta.-l-xylopyranoside, Methyl 5-c-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5s)-

48. Methyl (5s)-5-c-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-.beta.-l-xylopyranoside

2.4 Create Date
2008-07-07
3 Chemical and Physical Properties
Molecular Weight 424.9 g/mol
Molecular Formula C21H25ClO5S
XLogP33.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass424.1111228 g/mol
Monoisotopic Mass424.1111228 g/mol
Topological Polar Surface Area104 Ų
Heavy Atom Count28
Formal Charge0
Complexity476
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.


Treatment of type II diabetes mellitus


Treatment of type I diabetes mellitus


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Sodium-Glucose Transporter 2 Inhibitors

Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)


5.2 ATC Code

A10


A - Alimentary tract and metabolism

A10 - Drugs used in diabetes

A10B - Blood glucose lowering drugs, excl. insulins

A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors

A10BK06 - Sotagliflozin


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713810600,"product":"SOTAGLIFLOZIN(IN-HOUSE) (EXPORT INVOICENO:6124010017 DT:19.04.2024)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"EVA PHARMA","customerCountry":"EGYPT","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4700","totalValueFC":"4564.1","currency":"USD","unitRateINR":381135,"date":"23-Apr-2024","totalValueINR":"381135","totalValueInUsd":"4564.1","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"9332202","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732300200,"product":"SOTAGLIFLOZIN (EXPORT INVOICE NO:6124010425 DT:30.10.2024)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"MARCYRL PHARMACEUTICALS","customerCountry":"EGYPT","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"4500","totalValueFC":"2159.9","currency":"USD","unitRateINR":364544,"date":"23-Nov-2024","totalValueINR":"182272","totalValueInUsd":"2159.9","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"5845781","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""}]
23-Apr-2024
23-Nov-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1018899-04-1 / Sotagliflozin API manufacturers, exporters & distributors?

Sotagliflozin manufacturers, exporters & distributors 1

52

PharmaCompass offers a list of Sotagliflozin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sotagliflozin manufacturer or Sotagliflozin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sotagliflozin manufacturer or Sotagliflozin supplier.

PharmaCompass also assists you with knowing the Sotagliflozin API Price utilized in the formulation of products. Sotagliflozin API Price is not always fixed or binding as the Sotagliflozin Price is obtained through a variety of data sources. The Sotagliflozin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Sotagliflozin

Synonyms

1018899-04-1, Lx-4211, Lx4211, Lp-802034, (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol, 6b4zbs263y

Cas Number

1018899-04-1

Unique Ingredient Identifier (UNII)

6B4ZBS263Y

About Sotagliflozin

Sotagliflozin is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. Upon oral administration, sotagliflozin binds to and blocks both SGLT1 in the gastrointestinal (GI) tract and SGLT2 in the kidneys, thereby suppressing the absorption of glucose from the GI tract and the reabsorption of glucose by the proximal tubule into the bloodstream, respectively. This decreases glucose uptake and enhances the urinary excretion of glucose, which lowers and/or normalizes blood glucose levels. SGLT1 is the primary transporter responsible for glucose absorption from the GI tract. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.

Sotagliflozin Manufacturers

A Sotagliflozin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sotagliflozin, including repackagers and relabelers. The FDA regulates Sotagliflozin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sotagliflozin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Sotagliflozin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Sotagliflozin Suppliers

A Sotagliflozin supplier is an individual or a company that provides Sotagliflozin active pharmaceutical ingredient (API) or Sotagliflozin finished formulations upon request. The Sotagliflozin suppliers may include Sotagliflozin API manufacturers, exporters, distributors and traders.

click here to find a list of Sotagliflozin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Sotagliflozin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sotagliflozin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Sotagliflozin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Sotagliflozin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Sotagliflozin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sotagliflozin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Sotagliflozin suppliers with NDC on PharmaCompass.

Sotagliflozin GMP

Sotagliflozin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Sotagliflozin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sotagliflozin GMP manufacturer or Sotagliflozin GMP API supplier for your needs.

Sotagliflozin CoA

A Sotagliflozin CoA (Certificate of Analysis) is a formal document that attests to Sotagliflozin's compliance with Sotagliflozin specifications and serves as a tool for batch-level quality control.

Sotagliflozin CoA mostly includes findings from lab analyses of a specific batch. For each Sotagliflozin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Sotagliflozin may be tested according to a variety of international standards, such as European Pharmacopoeia (Sotagliflozin EP), Sotagliflozin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sotagliflozin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty